San Diego Pharmacy Pays $350,000 for Mishandling Controlled Substances

NEWS RELEASE SUMMARY - May 2, 2024

SAN DIEGO - Palm Care Pharmacy, a San Diego County pharmacy chain with a storefront in El Cajon, has paid $350,000 to resolve allegations that it diverted controlled substances, failed to keep necessary accounting records for controlled substances, and improperly sold pseudoephedrine chemical products.

The settlement arises from a U.S. Drug Enforcement Administration investigation into suspected illegal activity at Talimi International, Inc. d/b/a Palm Care Pharmacy. Based on an inventory audit conducted by the DEA and other investigative activities, the government concluded that Palm Care Pharmacy's El Cajon location committed multiple violations of the Controlled Substances Act and the Combat Methamphetamine Epidemic Act from 2018 through 2022.

The government alleged that Palm Care Pharmacy failed to control its inventory of controlled substances, failed to maintain a complete record of controlled substances and the transactions, and sold listed chemical products (e.g., pseudoephedrine) without the necessary training and certification. Palm Care Pharmacy's failure to control inventory resulted in unaccounted-for pills, including: opioids (oxycodone, hydrocodone, and tramadol), benzodiazepines (Xanax), and muscle relaxants (Soma). In addition to paying $350,000 to resolve the government's claims, Palm Care Pharmacy entered into a Memorandum of Agreement with the DEA requiring Palm Care Pharmacy to undertake additional measures to handle controlled substances properly and safely.

"Failure to manage inventory of controlled substances is not just a compliance issue, it's a public safety issue," said U.S. Attorney Tara McGrath. "Every untracked pill is a problem waiting to happen."

"Accurate record keeping prevents controlled substances from ending up in the wrong hands," said DEA Diversion Program Manager Rostant Farfan. "DEA will continue to hold registrants accountable to ensure they are operating within the closed system of distribution."

This settlement was the result of a coordinated effort by the U.S. Attorney's Office for the Southern District of California and the Drug Enforcement Administration.

To report a tip directly to a DEA representative regarding medical personnel writing suspicious opioid prescriptions and pharmacies dispensing large amounts of opioids, call (571) 324-6499 or visit the DEA's website (https://www.deadiversion.usdoj.gov/) and click on "Report Illicit Pharmaceutical Activities."

This case was prosecuted by Assistant U.S. Attorney Dylan M. Aste.

The claims resolved by the settlement are allegations only, and there has been no determination of liability.